Yarrow Bioscience (YARW) Financials
Ticker history: VYNE became YARW (Yarrow Bioscience, Inc.) on . Earlier news and filings retain their original names and dates. View VYNE history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the YARW SEC filings page.
Yarrow Bioscience, Inc. (YARW) reported $570K in revenue for fiscal year 2025, up 13.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Yarrow remains a development-stage business: modest revenue growth has not yet offset research spending and recurring cash use.
Revenue increased to$570K in FY2025 while R&D fell to$19.2M , so the improved loss profile reflects reduced development spending alongside modest commercial growth. Operating cash flow remained near FY2024's level at-$33.1M versus-$34.0M , showing that accounting improvement has not materially changed cash requirements.
Assets fell to
R&D was
Financial Health Signals
We do not publish a peer-relative financial health score for Yarrow Bioscience, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Yarrow Bioscience, Inc. scores 4.19, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $165.7M against total liabilities of $2.4M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Yarrow Bioscience, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
Yarrow Bioscience, Inc. reported a net loss of $26.5M while operations used $33.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Yarrow Bioscience, Inc. generated $97K in revenue in Q2 2026. This represents an increase of 40.6% from the same quarter a year earlier. Against the prior quarter it is up 12.8%.
Yarrow Bioscience, Inc.'s EBITDA was -$3.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Yarrow Bioscience, Inc. reported a net loss of $3.0M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Yarrow Bioscience, Inc. held $22.9M in cash against $0 in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Yarrow Bioscience, Inc.'s quarterly ROE was -13.6% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Yarrow Bioscience, Inc. invested $788K in research and development in Q2 2026. This represents a decrease of 83.9% from the same quarter a year earlier. Against the prior quarter it is down 3.5%.
Not reported for Q2 2026.
Not reported for Q2 2026.
YARW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'26Filing | Q4'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing |
|---|---|---|---|---|---|---|---|---|
| Revenue | $97K+40.6% | $86K-57.4% | N/A | $69K-65.2% | $202K+106.1% | $84K+10.5% | $121K+6.1% | $198K+46.7% |
| R&D Expenses | $788K-83.9% | $817K-86.7% | N/A | $4.9M-33.2% | $6.1M+65.2% | $9.7M+220.5% | $10.2M+208.9% | $7.3M+1.0% |
| SG&A Expenses | $2.4M-11.7% | $3.1M-5.8% | N/A | $2.7M-17.0% | $3.3M-13.1% | $3.2M-18.4% | $3.0M-2.2% | $3.3M+2.1% |
| Operating Income | -$3.1Mn/m | -$3.8Mn/m | N/A | -$7.5Mn/m | -$9.2Mn/m | -$12.8Mn/m | -$13.1Mn/m | -$10.4Mn/m |
| EBITDA | -$3.1Mn/m | -$3.8Mn/m | N/A | -$7.5Mn/m | -$9.2Mn/m | N/A | N/A | -$10.4Mn/m |
| Income Tax | $0n/m | $0n/m | N/A | $0n/m | $0n/m | $4Kn/m | $0n/m | $0n/m |
| Net Income | -$3.0Mn/m | -$3.6Mn/m | N/A | -$5.8Mn/m | -$8.6Mn/m | -$12.0Mn/m | -$12.2Mn/m | -$9.4Mn/m |
| EPS (Basic) | -$3.51 | -$4.00 | N/A | -$6.73n/m | -$10.00 | -$14.00 | -$14.50 | -$11.00 |
| EPS (Diluted) | -$3.51 | -$4.00 | N/A | -$6.73n/m | -$10.00 | -$14.00 | -$14.50 | -$11.00 |
| Diluted Shares (Avg) | 858,000 | 855,360 | N/A | 855,000+0.4% | 853 | N/A | 851,740 | 851,720 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
YARW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'26Filing | Q4'2510-Q | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $23.6M-47.2% | $25.9M-54.1% | $30.2M-54.9% | $44.7M-48.4% | $56.4M-38.5% | $66.9M-31.5% | $76.2M+295.5% | $86.6M+247.2% |
| Current Assets | $23.5M-46.9% | $25.8M-53.0% | $30.0M-53.4% | $44.3M-47.1% | $54.9M-39.1% | $64.4M-32.9% | $73.5M+319.9% | $83.8M+264.9% |
| Cash & Equivalents | $22.9M+4.0% | $24.6M-12.7% | $24.0M+20.6% | $22.0M-25.5% | $28.2M+48.0% | $19.9M-34.9% | $16.3M+5.3% | $29.6M+43.5% |
| Short-Term Investments | $0-100.0% | $297K-98.7% | $5.0M-88.0% | $17.6M-63.7% | $22.1M-67.0% | $41.6M-33.6% | $53.9Mn/m | $48.5Mn/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $1.5M-73.6% | $1.2M-89.9% | $2.4M-83.8% | $5.8M-50.5% | $12.3M+48.0% | $14.8M+65.6% | $12.7M+63.1% | $11.8M+53.2% |
| Current Liabilities | $1.5M-73.6% | $1.2M-89.9% | $2.4M-83.8% | $5.8M-50.3% | $12.3M+77.4% | $14.8M+96.6% | $12.7M+96.3% | $11.8M+84.4% |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $25K-98.1% |
| Long-Term Debt | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Equity | $22.1M-43.3% | $24.6M-44.2% | $27.8M-46.7% | $38.9M-48.1% | $44.1M-47.1% | $52.1M-41.3% | $63.5M+452.3% | $74.9M+333.5% |
| Retained Earnings | -$764.2Mn/m | -$761.2Mn/m | -$757.7Mn/m | -$745.5Mn/m | -$739.8Mn/m | -$731.2Mn/m | -$719.1Mn/m | -$707.0Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
YARW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'26Filing | Q4'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.0Mn/m | -$4.1Mn/m | N/A | -$10.8Mn/m | -$11.5Mn/m | -$9.0Mn/m | -$8.5Mn/m | -$8.5Mn/m |
| Depreciation & Amortization | $6K0.0% | $6K0.0% | N/A | $6Kn/m | $6Kn/m | N/A | N/A | $0n/m |
| Stock-Based Compensation | $436K-17.6% | $474K-37.9% | N/A | $529K-40.2% | $763K-22.5% | N/A | $734K-14.9% | $885K+1.0% |
| Investing Cash Flow | $300K-93.6% | $4.7M-76.3% | N/A | $4.7M-75.4% | $19.8Mn/m | $12.7Mn/m | -$4.8Mn/m | $19.0Mn/m |
| Financing Cash Flow | -$14Kn/m | -$15Kn/m | N/A | -$34Kn/m | -$87Kn/m | -$132K-100.2% | -$2Kn/m | -$2Kn/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
YARW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'26Filing | Q4'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3197.9% | -4437.2% | N/A | -10930.4% | -4553.0% | -15202.4% | -10819.0% | -5250.5% |
| Net Margin | -3100.0% | -4168.6% | N/A | -8340.6% | -4262.9% | -14311.9% | -10047.1% | -4750.5% |
| Return on Equity | -13.6%+1.2pp | -14.5%+5.0pp | N/A | -14.8%-2.2pp | -19.5%-12.0pp | -23.1%-16.1pp | -19.1%+38.1pp | -12.6%+45.7pp |
| Return on Assets | -12.7%+0.1pp | -13.9%+1.4pp | N/A | -12.9%-2.0pp | -15.3%-8.4pp | -18.0%-11.6pp | -16.0%+18.2pp | -10.9%+29.4pp |
| Current Ratio | 15.26+7.7x | 20.86+16.4x | 12.53+8.2x | 7.60+0.5x | 4.47-8.6x | 4.35-8.4x | 5.81+3.1x | 7.13+3.5x |
| Debt-to-Equity | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x |
| Liabilities-to-Equity | 0.07-0.1x | 0.05-0.2x | 0.09-0.2x | 0.150.0x | 0.28+0.2x | 0.28+0.2x | 0.20-0.5x | 0.16-0.3x |
| Asset Turnover | 0.000.0x | 0.000.0x | N/A | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Yarrow Bioscience, Inc. YARW | FY2025 | $570K | -$26.5M | N/A | $165.7M | — |
| Compass Therapeutics, Inc. CMPX | FY2025 | $0 | -$66.5M | N/A | $147.7M | — |
| Cue Biopharma, Inc. CUE | FY2025 | $27.5M | -$26.6M | -96.9% | $127.1M | 64/100 |
| Protara Therapeutics, Inc. TARA | FY2025 | N/A | -$57.4M | N/A | $150.2M | — |
| Adagene Inc. ADAG | FY2025 | $7.7M | -$17.6M | N/A | $134.3M | 65/100 |
| Inovio Pharmaceuticals, Inc. INO | FY2025 | $65K | -$84.9M | N/A | $262.3M | — |
Where Yarrow Bioscience, Inc. Ranks
Frequently Asked Questions
Yarrow Bioscience, Inc. (YARW) reported $570K in total revenue for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Yarrow Bioscience, Inc. (YARW) revenue grew by 13.8% year-over-year, from $501K to $570K in fiscal year 2025.
No, Yarrow Bioscience, Inc. (YARW) reported a net loss of $26.5M in fiscal year 2025.
Yarrow Bioscience, Inc. (YARW) had EBITDA of -$29.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Yarrow Bioscience, Inc. (YARW) had $24.0M in cash and equivalents against $0 in long-term debt.
Yarrow Bioscience, Inc. (YARW) has a return on equity of -95.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Yarrow Bioscience, Inc. (YARW) recorded an outflow of $33.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Yarrow Bioscience, Inc. (YARW) recorded an outflow of $33.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Yarrow Bioscience, Inc. (YARW) had $30.2M in total assets as of fiscal year 2025, including both current and long-term assets.
Yarrow Bioscience, Inc. (YARW) reported no capital expenditure during fiscal year 2025.
Yarrow Bioscience, Inc. (YARW) invested $19.2M in research and development during fiscal year 2025.
Yarrow Bioscience, Inc. (YARW) had a current ratio of 12.53 as of fiscal year 2025, which is generally considered healthy.
Yarrow Bioscience, Inc. (YARW) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Yarrow Bioscience, Inc. (YARW) had a liabilities-to-equity ratio of 0.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Yarrow Bioscience, Inc. (YARW) had a return on assets of -87.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Yarrow Bioscience, Inc. (YARW) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $165.7M as of Nov 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Yarrow Bioscience, Inc. (YARW) trades at 291x sales, its market capitalization divided by $570K revenue, FY2025. The market capitalization is $165.7M as of Nov 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Yarrow Bioscience, Inc. (YARW) held $29.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $33.1M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Yarrow Bioscience, Inc. (YARW) has an Altman Z-Score of 4.19, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Yarrow Bioscience, Inc. (YARW) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Yarrow Bioscience, Inc. (YARW) reported a net loss of $26.5M while operations used $33.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.